The Mycobacterium tuberculosis peptidoglycan is cross-linked mainly by L,D-transpeptidases (LDTs), which are efficiently inactivated by a single ␤-lactam class, the carbapenems. Development of carbapenems for tuberculosis treatment has recently raised considerable interest since these drugs, in association with the ␤-lactamase inhibitor clavulanic acid, are uniformly active against extensively drug-resistant M. tuberculosis and kill both exponentially growing and dormant forms of the bacilli. We have purified the five L,D-transpeptidase paralogues of M. tuberculosis (Mt1 to -5) and compared their activities with those of peptidoglycan fragments and carbapenems. The five LDTs were functional in vitro since they were active in assays of peptidoglycan cross-linking (Mt5), ␤-lactam acylation (Mt3), or both (Mt1, Mt2, and Mt4). Mt3 was the only LDT that was inactive in the crosslinking assay, suggesting that this enzyme might be involved in other cellular functions such as the anchoring of proteins to peptidoglycan, as shown in Escherichia coli. Inactivation of LDTs by carbapenems is a two-step reaction comprising reversible formation of a tetrahedral intermediate, the oxyanion, followed by irreversible rupture of the ␤-lactam ring that leads to formation of a stable acyl enzyme. Determination of the rate constants for these two steps revealed important differences (up to 460-fold) between carbapenems, which affected the velocity of oxyanion and acyl enzyme formation. Imipenem inactivated LDTs more rapidly than ertapenem, and both drugs were more efficient than meropenem and doripenem, indicating that modification of the carbapenem side chain could be used to optimize their antimycobacterial activity.
T uberculosis (TB) remains the second-leading infectious disease causing mortality, after AIDS, and it is estimated that one-third of the world's population is infected with Mycobacterium tuberculosis. According to the 2012 WHO report, there were 8.7 million new TB cases and 1.4 million deaths due to the disease in 2011 (1) . TB treatment requires at least 6 months of chemotherapy with multiple drugs due to the poor efficacy of available antibiotics against particular forms of the M. tuberculosis bacilli that do not replicate (2, 3) . Inappropriate use of the two first-line anti-TB drugs, isoniazid and rifampin, leads to the emergence of bacilli that are resistant to these drugs (multidrug-resistant M. tuberculosis [MDR-TB]), and widespread dissemination of these bacilli represents an obstacle to tuberculosis control (1) . In 2011, the WHO estimated that there were 630,000 MDR-TB cases. The extensive use of second-line drugs has led to emergence of extensively drug-resistant M. tuberculosis (XDR-TB), which shows a very poor prognosis with an increasing mortality rate (4) .
Except for bedaquiline, all drugs used to treat tuberculosis were approved more than 45 years ago, illustrating the complexity of TB drug development. ␤-Lactams are not used for TB treatment since M. tuberculosis produces a broad spectrum ␤-lactamase, BlaC, which inactivates all ␤-lactams with various efficiencies (5) . However, BlaC is irreversibly inactivated by clavulanic acid, and the combination of this ␤-lactamase inhibitor with ␤-lactams of the carbapenem class has been reported to be bactericidal in vitro (6, 7) . The combination is active against both exponentially growing M. tuberculosis and nonreplicating forms of the bacilli (7) . Furthermore, the combination is uniformly active against XDR strains (7) .
Antibiotics of the ␤-lactam family inhibit the last step of peptidoglycan polymerization. In most bacteria, the drugs inactivate the essential D,D-transpeptidase activity of classical penicillinbinding proteins (PBPs) (8, 9) . These enzymes cross-link glycan chains by forming 4¡3 peptide bonds connecting residues at the fourth and third positions of stem peptides (Fig. 1) . Only 20% of the peptidoglycan cross-links are of the 4¡3 type in mycobacteria, indicating that classical PBPs may only have a minor role in peptidoglycan polymerization (10) . The majority of the crosslinks are of the 3¡3 type and are formed by L,D-transpeptidases (LDTs) (Fig. 1 ). PBPs and LDTs are structurally unrelated (11) , contain active-site serine and cysteine residues (12) , and use stem pentapeptide and tetrapeptide as the acyl donor substrate (12), respectively. Since pentapeptide is assembled in the cytoplasm, formation of the tetrapeptide donor substrate of LDTs requires a D,D-carboxypeptidase activity for cleaving the terminal D-Ala residue of peptidoglycan precursors (13, 14) .
␤-Lactam antibiotics inactivate peptidoglycan transpeptidases by forming a covalent adduct with the enzyme active-site residue.
The reaction is analogous to the first step of the transpeptidation reaction that leads to enzyme acylation by the donor stem peptide (15) . LDTs are efficiently inactivated by a single class of ␤-lactams, the carbapenems, such as imipenem, meropenem, ertapenem, and doripenem (16) (Fig. 2) . LDTs are likely to be the essential targets of carbapenems in M. tuberculosis, since these enzymes are responsible for formation of a substantial majority of the crosslinks in both the exponential and stationary phases of growth (10, 17) . However, the D,D-carboxypeptidase activity of PBPs is an additional target, since tetrapeptide production is essential to gener-ate the tetrapeptide donor substrate of LDTs (12, 14, 17) . Classical D,D-transpeptidases may also be essential, although these enzymes have a minor contribution to peptidoglycan cross-linking.
The chromosome of M. tuberculosis strain H37Rv encodes five LDTs paralogues. Ldt Mt1 and Ldt Mt2 are functional in an in vitro peptidoglycan cross-linking assay and are thought to have distinct functions in vivo (10, 18) . Ldt Mt2 is essential for virulence in a mouse model of acute infection (18) , whereas Ldt Mt1 may have a role in adaptation to the nonreplicative state of the bacilli (10) . The roles of the three remaining LDTs have not been investigated. To further characterize the targets of carbapenems in M. tuberculosis, we have purified the five L,D-transpeptidase paralogues and compared the in vitro activities of the enzymes with respect to peptidoglycan dimer formation and acylation by carbapenems.
MATERIALS AND METHODS
Production and purification of L,D-transpeptidases. Recombinant plasmids for production of the soluble form of Ldt Mt1 (Rv0116c) containing an N-terminal hexahistidine tag have been previously described (19) . For production of Ldt Mt2 , Ldt Mt3 , Ldt Mt4 , andLdt Mt5 , portions of the genes from M. tuberculosis H37Rv were amplified by PCR using oligonucleotides described in Table 1 . Heteroduplexes containing cohesive ends were ligated with vector pET-TEV digested with NdeI plus XhoI as previously described (19) . Escherichia coli BL21(DE3) harboring recombinant plasmids was grown at 37°C with vigorous shaking in 2 liters of brain heart infusion broth (Difco) containing kanamycin (50 g/ml) to an optical density at 600 nm of 0.9. Isopropyl-␤-D-thiogalactopyranoside was added (0.5 mM), and incubation was continued for 18 h at 16°C. LDTs were purified from clarified lysates by affinity chromatography on Ni 2ϩ -nitrilotriacetate-agarose resin (Sigma) and by size exclusion chromatography (Superdex 75 HL26/60 column; GE HealthCare) in 100 mM sodium phosphate buffer (pH 6.4) containing 300 mM NaCl. L,D-Transpeptidases were concentrated by ultrafiltration (Amicon Ultra-4 centrifugal filter devices; Millipore) to a final concentration of ca. 1.5 mg/ml and stored at Ϫ65°C in the same buffer.
Mass spectrometry analyses of L,D-transpeptidase acylation by carbapenems. The formation of drug-enzyme adducts was tested by incubating L,D-transpeptidases (20 M) with carbapenems (100 M) at 20°C in 100 mM sodium phosphate buffer (pH 6.0). Five microliters of acetonitrile and 1 l of 1% formic acid were added, and the reaction mixture was directly injected into the mass spectrometer (Qstar Pulsar I; Applied Biosystems) at a flow rate of 0.05 ml/min (acetonitrile, 50%; water, 49.5%; formic acid, 0.5% [by volume]). Spectra were acquired in the positive mode as previously described (16) .
Kinetics of L,D-transpeptidase inactivation by carbapenems. Fluorescence kinetic data were acquired with a stopped-flow apparatus (RX-2000; Applied Biophysics) coupled to a spectrofluorometer (Cary Eclipse; Varian) in 100 mM sodium phosphate (pH 6.0) at 10°C. Kinetic constants for LDT acylation by carbapenems were calculated as previously described (19, 20) . The rates of hydrolysis of acyl enzymes were determined by spectrophotometry in sodium phosphate buffer (100 mM; pH 6.0) at 20°C in a Cary 100 spectrophotometer (Cary 100-Bio; Varian) as previously described (19) .
Mass spectrometry analyses of transpeptidation reaction products. The disaccharide tetrapeptide containing amidated meso-diaminopimelic
-D-Ala 4 ) was purified from Mycobacterium abscessus strain CIP104536T, and the concentration was determined by amino acid analysis after acid hydrolysis (21) . In vitro formation of muropeptide dimers by LDTs (10 M) was tested in 10 l of 20 mM sodium phosphate buffer (pH 6.4) containing 60 mM NaCl and 4 mM disaccharide tetrapeptide. The reaction mixture was incubated for 2 h at 37°C and analyzed by electrospray mass spectrometry in the positive mode (Qstar Pulsar I; Applied Biosystems) as previously described (22) . D-Met (1 mM) was added to the reaction mixture to assay the exchange of D-Ala 4 by D-Met. The transpeptidases assayed were also tested with disaccharide pentapeptide GlcNAc-MurNGlyc-L-Ala
, which was purified from M. abscessus strain CIP104536T.
RESULTS

Covalent inactivation of L,D-transpeptidases by carbapenems.
LDTs were independently incubated with four carbapenems (imipenem, meropenem, ertapenem, and doripenem), and formation of covalent adducts was assayed by electrospray mass spectrometry (Table 2) . Mass increments corresponding to the masses of the antibiotics were detected, indicating that adducts were generated by formation of a thioester bond between the sulfhydryl group of the L,D-transpeptidase active-site cysteine and the carbonyl group of the carbapenem ␤-lactam ring (Fig. 2) (16) . Formation of covalent adducts was not detected for Ldt Mt5 , whereas the four remaining L,D-transpeptidases were acylated by each of the four carbapenems (Table 2) . Thus, only four of the five M. tuberculosis L,D-transpeptidases are inactivated by carbapenems.
Kinetics of enzyme acylation. We have previously shown that L,D-transpeptidase inactivation by carbapenems is a two-step reaction ( Fig. 2) (20, 23) . The first step is reversible and leads to formation of a tetrahedral intermediate, the oxyanion (EI ox ). The second step is irreversible and leads to formation of the acyl enzyme (EI*). Fluorescence kinetics indicated that Ldt Mt1 , Ldt Mt2 , Ldt Mt3 , and Ldt Mt4 , but not Ldt Mt5 , were inactivated by carbapenems (Table 3) , in agreement with mass spectrometry analyses (Table 2). The rate constants k 1 and k 2 for formation of the oxyanion and acyl enzyme, respectively, were determined by spectrofluorometry according to previously described procedures (20, 23) . The k 2 /K app ratio provides an evaluation of the overall efficacy of the reaction based on estimates of the disappearance of free enzyme. Important variations in the velocity of the acylation reaction were detected between LDTs ( Mt3 , and Ldt Mt4 . Among these three enzymes, Ldt Mt3 was acylated more efficiently by meropenem than Ldt Mt4 , but similar values were observed for ertapenem and doripenem. For all carbapenems, the efficiency of acylation was the lowest for Ldt Mt2 .
Important variations in the velocity of the acylation reaction were also detected between carbapenems. The dynamic range of k 2 /K app ratios reached 460 for inactivation of Ldt Mt4 by imipenem and meropenem. Based on the k 2 /K app ratios (Table 3) , the overall efficacies of the four carbapenems could be ranked as imipenem Ͼ ertapenem Ͼ meropenem ϭ doripenem.
In vitro cross-linking of purified peptidoglycan fragments. Substrates of the L,D-transpeptidases were prepared by isolation of M. abscessus sacculi, treatment with muramidases, and purification of the resulting disaccharide peptide fragments by reversephase high-pressure liquid chromatography (rpHPLC). Incubation of Ldt Mt1 , Ldt Mt2 , Ldt Mt4 , and Ldt Mt5 with a disaccharide tetrapeptide resulted in formation of peptidoglycan dimers containing a 3¡3 cross-link ( Fig. 1 and Table 4 
DISCUSSION
The increasing incidence of MDR and XDR tuberculosis indicates that there is an urgent need for new anti-TB drugs (24) . In this context, LDTs are attractive targets, since the M. tuberculosis peptidoglycan contains a majority of 3¡3 cross-links formed by these enzymes (10, 17) . To investigate peptidoglycan inhibition by ␤-lactams, we have characterized five M. tuberculosis L,D-transpeptidase paralogues with respect to peptidoglycan dimer formation and acylation by carbapenems. We have obtained functional forms of the five L,D-transpeptidases, since each enzyme was active in the cross-linking assay (Mt5), the ␤-lactam acylation assay (Mt3), or both (Mt1, Mt2, and Mt4). Ldt Mt3 was not active in the peptidoglycan cross-linking assay. In E. coli, two L,D-transpeptidases catalyze peptidoglycan crosslinking, whereas three additional paralogues anchor the Braun lipoprotein to peptidoglycan (25, 26) . This observation suggests that Ldt Mt3 may perform as-yet-unknown cross-linking reactions in M. tuberculosis.
Ldt Mt5 was not inactivated by carbapenems but was active in the peptidoglycan cross-linking assay. The antibacterial activity of carbapenems suggests that Ldt Mt5 cannot compensate for the activity of the other L,D-transpeptidases. In Streptococcus pneumoniae and E. coli, it has been established that multiple D,D-transpeptidases are essential for peptidoglycan polymerization (9) .
Carbapenems also inactivate D,D-carboxypeptidase DacB and prevent formation of tetrapeptide stems in the M. tuberculosis peptidoglycan (17) . Although D,D-carboxypeptidases are considered unessential in E. coli (27) , these enzymes may be required for peptidoglycan polymerization in M. tuberculosis, since they generate the tetrapeptide donor stem for formation of 3¡3 crosslinks by LDTs (17) . In agreement, we have shown here that the four LDTs that are active in the cross-linking assay are specific for donor substrates containing a stem tetrapeptide. Ldt fs from Enterococcus faecalis is the only known L,D-transpeptidase that uses both tetrapeptide and pentapeptide stems as acyl donors (22) . In Enterococcus faecium, stem tetrapeptides are produced in the cytoplasm by metallo-D,D-carboxypeptidase DdcY, which cleaves the C-terminal D-Ala residue of UDP-MurNAc pentapeptide (14) .
The genome of M. tuberculosis does not code for a DdcY homologue, indicating that tetrapeptide stems are produced only by D,D-carboxypeptidases belonging to the PBP family in this species.
We have previously shown that ertapenem and imipenem are the most efficient ␤-lactams for in vitro inactivation of Ldt Mt1 , with high rate constants for formation of the oxyanion (k 1 ) and acylation (k 2 ) (19) . The meropenem side chain moderately impaired drug binding (lower k 1 ), whereas that of doripenem had an additional unfavorable impact on the acylation step (lower k 2 ) (19) . The analyses of Ldt Mt2 , Ldt Mt3 , and Ldt Mt4 reported in the present study revealed greater differences between carbapenems. For these enzymes, inactivation was more rapid with imipenem than with ertapenem, whereas acylation by meropenem and doripenem was very slow. These results indicate that modification of the side chains of carbapenems could be used to optimize the antibacterial activity of these drugs. Detection of multiple LDTs with highly diverse inactivation kinetics also suggests that combination therapy including two ␤-lactams may lead to synergism. 
